Literature DB >> 7887664

Lichenoid graft-vs-host disease in an autologous bone marrow transplant recipient.

R W Martin1, E R Farmer, V L Altomonte, G B Vogelsang, G W Santos.   

Abstract

BACKGROUND: Graft-vs-host disease (GVHD) represents one of the major complications of allogeneic bone marrow transplantation (BMT) but is less common in autologous BMT. Following autologous BMT, chronic GVHD has been reported in only four patients, all of whom had a self-limited sclerodermoid form. Lichenoid chronic GVHD has not been previously reported in an autologous BMT patient. OBSERVATIONS: Mucosal and cutaneous lichenoid lesions and histologic findings compatible with chronic lichenoid GVHD developed in a patient 35 days after autologous BMT was performed. The onset of clinical lesions at 35 days after BMT is not incongruent with the diagnosis of chronic lichenoid GVHD (rather than a graft-vs-host reaction) and may have been augmented by cyclosporin A in a manner similar to animal model experiments.
CONCLUSION: All forms of GVHD can and do occur following autologous BMT.

Entities:  

Mesh:

Year:  1995        PMID: 7887664

Source DB:  PubMed          Journal:  Arch Dermatol        ISSN: 0003-987X


  3 in total

1.  Acquired Omenn-like syndrome, a novel posttransplant autoaggression syndrome reversed by rapamycin.

Authors:  Donald C Vinh; Khalid Bin Dhuban; Helen Mason; Duncan Lejtenyi; Sungmi Jung; Donald C Sheppard; Damien Faury; Nada Jabado; Ciriaco A Piccirillo
Journal:  Clin Vaccine Immunol       Date:  2011-11-16

2.  Oral chronic graft-versus-host disease: report from the International Consensus Conference on clinical practice in cGVHD.

Authors:  Johannes K-H Meier; Daniel Wolff; Steve Pavletic; Hildegard Greinix; Martin Gosau; Hartmut Bertz; Stefanie J Lee; Anita Lawitschka; Sharon Elad
Journal:  Clin Oral Investig       Date:  2010-09-22       Impact factor: 3.573

3.  Skew in T cell receptor usage with polyclonal expansion in lesions of oral lichen planus without hepatitis C virus infection.

Authors:  A Gotoh; Y Hamada; N Shiobara; K Kumagai; K Seto; T Horikawa; R Suzuki
Journal:  Clin Exp Immunol       Date:  2008-09-08       Impact factor: 4.330

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.